Skip to main content

Advertisement

SpringerLink
Log in

Chemiluminescence Immunoassay Method of Urinary Liver Fatty-acid-binding Protein as a Promising Candidate for Kidney Disease

  • Research
  • Published:
Journal of Fluorescence Aims and scope Submit manuscript

Abstract

Liver fatty acid binding protein (L-FABP) is an intercellular lipid chaperone protein that selectively combines with unsaturated free fatty acids and transports them to mitochondria or peroxisomes. L-FABP is a promising biomarker for the early detection of renal diseases in humans. Herein a chemiluminescence method (CLIA) was demonstrated to measure the level of urinary L-FABP in the urinary samples. An anti-(L-FABP)-magnetic beads complex was prepared to capture the analyte target. Sensitivity, precision, accuracy, interference effect, high-dose hook effect of the developed assay were evaluated. Under the suitable experimental parameters, the established method have a wide linear range (0.01–10 ng/mL) and also showed a sufficiently low limit of detection of 0.0060 ng/mL. Besides, the satisfactory recoveries of the method in the urinary were ranged from 97.74%—112.32%, which was well within the requirement of clinical analysis. Furthermore, this proposed method has been successfully applied to the clinical determination of L-FABP in patients who have been diagnosed with kidney disease. The results showed that CLIA could accurately and rapidly determine the urinary level of L-FABP with high-throughput, which could be useful as a new tool to predict complications in patients with kidney disease. The clinical trial was approved by Shuyang Hospital of Traditional Chinese Medicine Ethics Committee: 20,210,202–001 at February 2, 2021.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data Availability

The datasets generated during and/or analyzed during the current study are not publicly available due to privacy and ethical restrictions but are available from the corresponding author on reasonable request.

References

  1. Zhang WR, Parikh CR (2019) Biomarkers of acute and chronic kidney disease. Annu Rev Physiol 81:309–333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Yerramilli M, Farace G, Quinn J, Yerramilli M (2016) Kidney disease and the nexus of chronic kidney disease and acute kidney injury. Vet Clin North Am Small Anim Pract 46:961–993

    Article  PubMed  Google Scholar 

  3. Ling XC, Kuo KL (2018) Oxidative stress in chronic kidney disease. Ren Replace Ther 4:53

    Article  Google Scholar 

  4. Basso PJ, Andrade-Oliveira V, Câmara NOS (2021) Targeting immune cell metabolism in kidney diseases. Nat Rev Nephrol 17:465–480

    Article  CAS  PubMed  Google Scholar 

  5. John KA, Norbert L, Peter A, Rashad BS, Emmanuel BA, Stuart GL, Charles HA, Michael J, Andreas K (2012) Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1–138

    Google Scholar 

  6. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative(ADQI) Group. Crit Care 8:R204–R212

    Article  PubMed  PubMed Central  Google Scholar 

  7. Hamadah AM, Gharaibeh K, Mara KC, Thompson KA, Lieske JC, Said S, Nasr SH, Leung N (2018) Urinalysis for the diagnosis of glomerulonephritis: role of dysmorphic red blood cells. Nephrol Dial Transpl 33:1397–1403

    Article  Google Scholar 

  8. Perazella MA (2015) The urine sediment as a biomarker of kidney disease. Am J Kidney Dis 66:748–755

    Article  CAS  PubMed  Google Scholar 

  9. Lei R, Huo R, Mohan C (2020) Current and emerging trends in point-of-care urinalysis tests, Expert Rev. Mol Diagn 20:69–84

    CAS  Google Scholar 

  10. Paglinawan AC, Cruz FRG, Valiente LD, Mendoza JPT, Chanliongco AM, Torres JB, Tungol RGS (2020) Measurement of specific gravity, urobilinogen, blood, protein and pH level of urine samples using raspberry Pi based portable urine test strip analyzer. In: Proc 2020 10th Int Conf Biomed Eng Technol ACM Tokyo Japan 58–63

  11. Seibert FS, Sitz M, Passfall J, Haesner M, Laschinski P, Buhl M, Bauer F, Babel N, Pagonas N, Westhoff TH (2018) Prognostic value of urinary calprotectin, NGAL and KIM-1 in chronic kidney disease. Kidney Blood Press Res 43:1255–1262

    Article  CAS  PubMed  Google Scholar 

  12. Duan S, Chen J, Wu L, Nie G, Sun L, Zhang C, Huang Z, Xing C, Zhang B, Yuan Y (2020) Assessment of urinary NGAL for differential diagnosis and progression of diabetic kidney disease. J Diabetes Complicat 34:107665

    Article  Google Scholar 

  13. Wu T-H, Li K-J, Yu C-L, Tsai C-Y (2018) Tamm-Horsfall protein is a potent immunomodulatory molecule and a disease biomarker in the urinary system. Molecules 23:200

    Article  PubMed  PubMed Central  Google Scholar 

  14. Milas O, Gadalean F, Vlad A, Dumitrascu V, Velciov S, Gluhovschi C, Bob F, Popescu R, Ursoniu S, Jianu DC, Matusz P, Pusztai AM, Secara A, Simulescu A, Stefan M, Patruica M, Petrica F, Vlad D, Petrica L (2020) Pro-inflammatory cytokines are associated with podocyte damage and proximal tubular dysfunction in the early stage of diabetic kidney disease in type 2 diabetes mellitus patients. J Diabetes Complicat 34:107479

    Article  Google Scholar 

  15. Portilla D, Dent C, Sugaya T, Nagothu KK, Kundi I, Moore P, Noiri E, Devarajan P (2008) Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 73:465–472

    Article  CAS  PubMed  Google Scholar 

  16. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Kimura K (2005) Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial. J Lab Clin Med 145:125–133

    Article  CAS  PubMed  Google Scholar 

  17. Takashima S, Nagamori Y, Ohata K, Oikawa T, Sugaya T, Kobatake Y, Nishii N (2021) Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs. J Vet Med Sci 83:1465–1471

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Li F, Guo L, Hu Y, Li Z, Liu J, He J, Cui H (2020) Multiplexed chemiluminescence determination of three acute myocardial infarction biomarkers based on microfluidic paper-based immunodevice dual amplified by multifunctionalized gold nanoparticles. Talanta 207:120346

    Article  CAS  PubMed  Google Scholar 

  19. Kim J, Kim J, Rho THD, Lee JH (2014) Rapid chemiluminescent sandwich enzyme immunoassay capable of consecutively quantifying multiple tumor markers in a sample. Talanta 129:106–112

    Article  CAS  PubMed  Google Scholar 

  20. Yang L, Ni HJ, Li CL, Zhang XY, Wen K, Ke YB, Yang HJ, Shi WM, Zhang SX, Shen JZ, Wang ZH (2019) Development of a highly specific chemiluminescence aptasensor for sulfamethazine detection in milk based on in vitro selected aptamers. Sens Actuators B Chem 281:801–811

    Article  CAS  Google Scholar 

  21. Li ZB, Cui PL, Liu J, Liu JX, Wang JP (2020) Production of generic monoclonal antibody and development of chemiluminescence immunoassay for determination of 32 sulfonamides in chicken muscle. Food Chem 311:125966

    Article  CAS  PubMed  Google Scholar 

  22. Han XS, Cao MD, Wu MR, Wang YJ, Yu CM, Zhang CW, Yu HD, Wei JF, Li L, Huang W (2019) A paper-based chemiluminescence immunoassay device for rapid and high-throughput detection of allergen-specific IgE. Analyst 144:2584–2593

    Article  CAS  PubMed  Google Scholar 

  23. Wang G, Wan Y, Lin G, Li Z, Dong Z, Liu T (2020) Development of a novel chemiluminescence immunoassay for the detection of procalcitonin. J Immunol Methods 484–485:112829

    Article  PubMed  Google Scholar 

  24. Fu HJ, Yuan LP, Shen YD, Liu YX, Liu B, Zhang SW, Xie ZX, Lei HT, Sun YM, Xu ZL (2018) A full-automated magnetic particle-based chemiluminescence immunoassay for rapid detection of cortisol in milk. Anal Chim Acta 1035:129–135

    Article  CAS  PubMed  Google Scholar 

  25. Vakh C, Pochivalov A, Koronkiewicz S, Kalinowski S, Postnov V, Bulatov A (2019) A chemiluminescence method for screening of fluoroquinolones in milk samples based on a multi-pumping flow system. Food Chem 270:10–16

    Article  CAS  PubMed  Google Scholar 

  26. Sathishkumar N, Toley BJ (2020) Development of an experimental method to overcome the hook effect in sandwich-type lateral flow immunoassays guided by computational modelling. Sens Actuators B Chem 324:128756

    Article  CAS  Google Scholar 

  27. Lok C, Frijstein M, van Trommel N (2021) Clinical presentation and diagnosis of Gestational Trophoblastic Disease. Best Pract Res Clin Obstet Gynaecol 74:42–52

    Article  PubMed  Google Scholar 

  28. Mei Y, Li C, Yang S, Chen W, Liu R, Xu K (2021) A novel biosensor for the rapid and high-sensitive detection of mercury based on cleavable phosphorothioate RNA probe. Sens Actuators B Chem 337:129756

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported from National Natural Science Foundation of China (81860399), the Provincial Youth Science Fund of Jiangxi Province (20142BAB215072). The Science and Technology Key R&D Program of Jiangxi Province (20202BBG72001).

Author information

Author notes

  1. Lisong Niu and Lanya Li contributed equally to this work.

Authors and Affiliations

  1. The No. 4 People’ Hospital of Hengshui, Hengshui, Hebei, 053000, People’s Republic of China

    Lisong Niu

  2. Shuyang Hospital of Traditional Chinese Medicine, Suqian, Jiangsu, 223600, People’s Republic of China

    Lanya Li

  3. Experimental Teaching Center of Bioengineering, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, 430070, People’s Republic of China

    Jinshan Li

  4. Jiangsu MDK Biotech. Co., Ltd., Jiangsu, 223600, Suqian, People’s Republic of China

    Zhitian Chen, Jiayuan Lin & Bo Zhang

  5. The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China

    Xiaoling Fu

Authors
  1. Lisong Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lanya Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jinshan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhitian Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiayuan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoling Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Lisong Niu designed the study and drafted the manuscript, Lanya Li and Jinshan Li assisted in patient recruitment, provided clinical treatments and contributed critical views the study. Zhitian Chen and Jiayuan Lin performed the experiments and data analysis, supervised the study. Bo Zhang and Xiaoling Fu critically reviewed the manuscript. All co-authors approved the final version of the manuscript.

Corresponding authors

Correspondence to Bo Zhang or Xiaoling Fu.

Ethics declarations

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number at the Shuyang Hospital of Traditional Chinese Medicine Ethics Committee: 20210202–001) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent to Participate

Informed consent was obtained from all individual participants included in the study.

Consent to Publish

Not applicable.

Conflict of Interest

Authors declare that they have no competing interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOC 98 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niu, L., Li, L., Li, J. et al. Chemiluminescence Immunoassay Method of Urinary Liver Fatty-acid-binding Protein as a Promising Candidate for Kidney Disease. J Fluoresc 33, 1191–1200 (2023). https://doi.org/10.1007/s10895-022-03120-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10895-022-03120-z

Keywords

Search

Navigation